RNAZ Insider Trading Activity and SEC Form 4 Filings
RNAZ insider trading summary
No open-market insider purchases or sales of Transcode Therapeutics, Inc. (RNAZ) have been reported on SEC Form 4 in the past 12 months.
Latest RNAZ insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 28, 2023 | Thomas A Fitzgerald | Chief Financial Officer | Buy | $25K (49,350 @ $0.51) |
| Sep 28, 2023 | Robert Michael Dudley | Chief Executive Officer | Buy | $50K (98,000 @ $0.51) |
| Jun 21, 2023 | Robert Michael Dudley | Chief Executive Officer | Buy | $32K (12,000 @ $2.65) |
| Jun 20, 2023 | Robert Michael Dudley | Chief Executive Officer | Buy | $17K (6,607 @ $2.55) |
| Jun 9, 2023 | Robert Michael Dudley | Chief Executive Officer | Buy | $52K (19,000 @ $2.76) |
| Sep 14, 2022 | Robert Michael Dudley | Chief Executive Officer | Buy | $23K (20,000 @ $1.15) |
| Jun 16, 2022 | Thomas A Fitzgerald | Chief Financial Officer | Buy | $15K (12,000 @ $1.27) |
| May 31, 2022 | Robert Michael Dudley | Chief Executive Officer | Buy | $4K (2,000 @ $1.87) |
| May 27, 2022 | Robert Michael Dudley | Chief Executive Officer | Buy | $52K (28,000 @ $1.84) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.